Xilio Therapeutics Inc ( (XLO) ) has released its Q3 earnings. Here is a breakdown of the information Xilio Therapeutics Inc presented to its investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Xilio Therapeutics Inc. is a clinical-stage biotechnology company focused on developing tumor-activated immuno-oncology therapies to improve cancer treatment outcomes. In its latest earnings report for the quarter ending September 30, 2025, Xilio Therapeutics highlighted a significant increase in collaboration and license revenue, amounting to $19.1 million, compared to $2.3 million in the same period last year. Despite this revenue growth, the company reported a net loss of $16.3 million for the quarter, reflecting ongoing investments in research and development. Key financial metrics reveal that Xilio’s operating expenses rose to $21 million, driven by increased research and development costs. The company also reported a substantial change in the fair value of its common stock warrant liabilities, which negatively impacted its financial results. Looking ahead, Xilio Therapeutics remains focused on advancing its pipeline of immuno-oncology therapies and securing additional capital to support its operations, as it continues to face challenges related to its financial sustainability.